Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features

Table 3 Mean changes from baseline to last observation in all studies and the subset of positive studies

	Melancholic Status	Mean Change (SD)		p-value^a	p-value^b
		Duloxetine	Placebo
HAMD ₁₇ Total Score
All Studies	MEL (n = 1249)	-8.97 (7.36)	-6.57 (7.24)	<.001
	NON-MEL (n = 621)	-8.25 (6.55)	-6.20 (6.22)	<.001	.651
Positive Studies	MEL (n = 984)	-9.83 (7.20)	-7.03 (7.06)	<.001
	NON-MEL (n = 474)	-9.15 (6.23)	-6.47 (6.27)	<.001	.781
CGI-Severity
All Studies	MEL (n = 1251)	-1.52 (1.25)	-1.11 (1.21)	<.001
	NON-MEL (n = 621)	-1.47 (1.23)	-1.14 (1.19)	.001	.511
Positive Studies	MEL (n = 986)	-1.62 (1.25)	-1.16 (1.20)	<.001
	NON-MEL (n = 474)	-1.54 (1.13)	-1.15 (1.17)	<.001	.679
PGI-Improvement ^†	Mean (SD)
All Studies	MEL (n = 1249)	2.67 (1.27)	3.07 (1.27)	<.001
	NON-MEL (n = 621)	2.71 (1.31)	3.17 (1.27)	<.001	.865
Positive Studies	MEL (n = 984)	2.64 (1.26)	3.09 (1.27)	<.001
	NON-MEL (n = 474)	2.70 (1.28)	3.18 (1.32)	<.001	.912

ISSN: 1471-244X